|

Quemliclustat Clinical Trials

2 actively recruiting trials across 2 locations

▲ +1 trial since August 2026

Also known as: AB 680, AB-680, AB680, CD73 Inhibitor AB680

Pipeline

Phase 2: 1Phase 1/2: 1

Top Sponsors

  • Fred Hutchinson Cancer Center1
  • Catherine Spina1

Indications

  • Cancer2
  • Unresectable Ureter Urothelial Carcinoma1
  • Unresectable Renal Pelvis Urothelial Carcinoma1
  • Unresectable Bladder Urothelial Carcinoma1
  • Stage IV Ureter Cancer AJCC v81

New York, New York1 trial

Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer

Columbia University Irving Medical Center / NewYork-Presbyterian Hospital

Phase 2

Seattle, Washington1 trial

Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer

Fred Hutch/University of Washington Cancer Consortium

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.